Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14108152 | 0.89 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| Acetaldehyde SCHEMBL27973957 | 0.89 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9070633 | 0.89 | MEN1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL498377 | 0.88 | ALDH1A1 (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7791287 | 0.84 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL8583206 | 0.84 | SCN5A (0.43) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7791292 | 0.84 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL19337433 | 0.83 | DRD2 (0.41) | MAPTDRD2DRD4DRD3WDR5 | |
| SCHEMBL10178017 | 0.83 | DRD2 (0.41) | MAPTDRD2DRD4DRD3WDR5 | |
| SCHEMBL2259946 | 0.82 | CA12 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079674-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROETHOXYTOLUENES | Grindeks, a joint stock company (LV) | 2009-07-22 | — | — | EP | claimed |
| EP-2079692-A1 | PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYLMETHYL)-BENZAMIDE AND SALTS THEREOF | Grindeks, a joint stock company (LV) | 2009-07-22 | — | — | EP | claimed |
| WO-2008055849-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROETHOXYTOLUENES | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2008-05-15 | — | — | WO | claimed |
| WO-2008055851-A1 | PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYLMETHYL)-BENZAMIDE AND SALTS THEREOF | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2008-05-15 | — | — | WO | claimed |
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11693310-B2 | Blue curable resin composition, blue color filter, and display device including same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-07-04 | — | — | US | disclosed |
| US-11693310-B2 | Blue curable resin composition, blue color filter, and display device including same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-07-04 | — | — | US | disclosed |
| US-20230026907-A1 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | ORION CORP (FI) | 2023-01-26 | — | — | US | disclosed |
| WO-2022192487-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-11173145-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3865475-A1 | PROCESS FOR PREPARING PYRIDONE AMIDES WHICH ARE MODULATORS OF SODIUM CHANNELS AND INTERMEDIATE COMPOUNDS USED THEREIN | Vertex Pharmaceuticals Incorporated (US) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021131834-A1 | COLORED RESIN COMPOSITION | 住友化学株式会社 | 2021-07-01 | — | — | WO | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
| US-7202260-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones | SCHERING AG (DE) | 2007-04-10 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| US-6071927-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-06-06 | — | — | US | disclosed |
| EP-0906315-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997049710-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026907-A1 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SCN11A, HCN4, CACNA1F | NPC1 1238/4885RAB9A 3208/4885SMN1; SMN2 2050/4885 |
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | NPC1 1846/4885RAB9A 1737/4885SMN1; SMN2 3709/4885 |
| US-11173145-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | TPH2, TPH1, IDO2 | NPC1 2403/4885RAB9A 2473/4885SMN1; SMN2 4645/4885 |
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SCN11A, HCN4, CACNA1F | NPC1 1238/4885RAB9A 3208/4885SMN1; SMN2 2050/4885 |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | GCGR, GLP1R, GCG | NPC1 2228/4885RAB9A 2887/4885SMN1; SMN2 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.